



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENT
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

JUL 16 2003

#36

Charles Van Horn
Finnegan Henderson Farabow Dunner and Garrett
1300 I Street NW
Washington DC 20005-3315

Re: Patent Term Extension
Application for
U.S. Patent No. 4,758,579

Dear Mr. Van Horn:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,758,579 for a period of 5 years. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). The sample format for submitting information regarding the patent and the patent expiration date to the Orange Book is available on the FDA Internet web site at: <http://www.fda.gov/cder/orange/patdecl.pdf> or <http://www.fda.gov/cder/orange/patdecl.htm>. See also FDA Forms 3542 and 3542a.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Ferriter

Karin Ferriter
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: David T. Read
Health Assessment Policy Staff
Acting Director Health Assessment Policy Staff, CDER
Food and Drug Administration
1451 Rockville Pike, HFD-7
Rockville, MD 20852

RE: Protonix® (pantoprazole sodium)

FDA Docket No.: